The TearCare system has received 510(k) clearance from the FDA for the treatment of meibomian gland dysfunction, according to a press release from Sight Sciences.
The system works by providing localized heat therapy to soften or liquefy thickened meibum inside the glands to allow for more effective gland clearance.
The clearance is based on data from several studies, including OLYMPIA. Patients who underwent a single TearCare procedure had statistically significant improvements in mean tear film breakup time and meibomian gland secretion score at 1 month after treatment.
“While historic